Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Kellsye P Fabian"'
Autor:
James W Hodge, Michelle R Padget, Kellsye P Fabian, Joshua T Kowalczyk, Diana C Lopez, Austin TK Hoke, Clint T Allen, Mario Hermsen, Nyall R London,
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background While radiation and chemotherapy are primarily purposed for their cytotoxic effects, a growing body of preclinical and clinical evidence demonstrates an immunogenic potential for these standard therapies. Accordingly, we sought to characte
Externí odkaz:
https://doaj.org/article/b35c36192dca4f90a76f74544eca38d6
Autor:
Kellsye P Fabian
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Different types of tumors have varying susceptibility to immunotherapy and hence require different treatment strategies; these cover a spectrum ranging from ‘hot’ tumors or those with high mutational burden and immune infiltrates that
Externí odkaz:
https://doaj.org/article/8f12eebaf9ee42259fa91d4811cdf796
Autor:
Yvette Robbins, Sarah Greene, Jay Friedman, Paul E Clavijo, Carter Van Waes, Kellsye P Fabian, Michelle R Padget, Houssein Abdul Sater, John H Lee, Patrick Soon-Shiong, James Gulley, Jeffrey Schlom, James W Hodge, Clint T Allen
Publikováno v:
eLife, Vol 9 (2020)
Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations.
Externí odkaz:
https://doaj.org/article/c2df21fadf264488a0684e775401ddeb
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoi
Externí odkaz:
https://doaj.org/article/2cdc94ab811b4ee3a4c9aeb0ebba45c0
Autor:
Diana C. Lopez, Kellsye P. Fabian, Michelle R. Padget, Yvette L. Robbins, Joshua T. Kowalczyk, Wiem Lassoued, Danielle M. Pastor, Clint T. Allen, Gary L. Gallia, James L. Gulley, James W. Hodge, Nyall R. London
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionCancer stem cells (CSCs), a group of tumor-initiating and tumor-maintaining cells, may be major players in the treatment resistance and recurrence distinctive of chordoma. Characterizing CSCs is crucial to better targeting this subpopulat
Externí odkaz:
https://doaj.org/article/ba6819eb8a42444ebc7cdd19fe5b44dc
Autor:
Kellsye P. Fabian, James W. Hodge
Publikováno v:
Molecular Therapy: Oncolytics, Vol 23, Iss , Pp 266-276 (2021)
Natural killer (NK) cells are innate lymphocytes that recognize and clear infected and transformed cells. The importance of NK cells in tumor surveillance underlies the development of NK cell therapy as cancer treatment. The NK-92 cell line has been
Externí odkaz:
https://doaj.org/article/23fee5f32182465385a52465d1c49060
Autor:
S. Elizabeth Franks, Ginette S. Santiago-Sanchez, Kellsye P. Fabian, Kristen Solocinski, Paul L. Chariou, Duane H. Hamilton, Joshua T. Kowalczyk, Michelle R. Padget, Sofia R. Gameiro, Jeffrey Schlom, James W. Hodge
Publikováno v:
Cancer Immunology, Immunotherapy.
There is strong evidence that chemotherapy can induce tumor necrosis which can be exploited for the targeted delivery of immuno-oncology agents into the tumor microenvironment (TME). We hypothesized that docetaxel, a chemotherapeutic agent that induc
Autor:
James W. Hodge, Jeffrey Schlom, Houssein Abdul Sater, Rika Fujii, Benjamin Wolfson, Kristen Solocinski, Michelle R. Padget, Anthony S. Malamas, Kellsye P. Fabian
Supplemental figures s1-s3 and supplementary table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8283f054f681cf562a94a185e717e50
https://doi.org/10.1158/2326-6066.22543390
https://doi.org/10.1158/2326-6066.22543390
Autor:
James W. Hodge, Jeffrey Schlom, Houssein Abdul Sater, Rika Fujii, Benjamin Wolfson, Kristen Solocinski, Michelle R. Padget, Anthony S. Malamas, Kellsye P. Fabian
Immunotherapy of immunologically cold solid tumors may require multiple agents to engage immune effector cells, expand effector populations and activities, and enable immune responses in the tumor microenvironment (TME). To target these distinct phen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f8c7c67f98dcbaf90b406c99ca1760
https://doi.org/10.1158/2326-6066.c.6550240
https://doi.org/10.1158/2326-6066.c.6550240
Autor:
James W. Hodge, Patrick Soon-Shiong, Anjali Nandal, Nyall R. London, Michelle R Padget, Gary L. Gallia, Austin T.K. Hoke, Marijo Bilusic, Kellsye P Fabian
Publikováno v:
Cancer Res Commun
Chordoma is a rare tumor derived from notochord remnants that has a propensity to recur and metastasize despite conventional multimodal treatment. Cancer stem cells (CSC) are implicated in chordoma's resistant and recurrent behavior; thus, strategies